View Valuation2invest 将来の成長Future 基準チェック /06現在、 2investの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).お知らせ • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.お知らせ • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.お知らせ • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.お知らせ • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、2invest は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XTRA:2INV - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20252826N/AN/AN/A3/31/20252724N/AN/AN/A12/31/20242622-25-25N/A9/30/20241714N/AN/AN/A6/30/202485N/AN/AN/A3/31/202483N/AN/AN/A12/31/20239299N/A9/30/20236-3N/AN/AN/A6/30/20232-8N/AN/AN/A3/31/20233-15N/AN/AN/A12/31/20223-211616N/A9/30/20223-20N/AN/AN/A6/30/20223-20N/AN/AN/A3/31/20222-11N/AN/AN/A12/31/20212-2-33-33N/A9/30/20211-12N/AN/AN/A6/30/20211-12N/AN/AN/A3/31/2021056N/AN/AN/A12/31/2020055-27-27N/A9/30/2020036-9-9N/A6/30/2020036-8-8N/A3/31/20201-4-5-4N/A12/31/20190-33-2-2N/A9/30/2019-7-401N/A6/30/2019-4-3-10N/A3/31/2019-1-3N/A0N/A12/31/20181-3N/A0N/A9/30/201812-2N/A-1N/A6/30/201810-3N/A-2N/A3/31/20189-3N/A-2N/A12/31/20178-4N/A-3N/A9/30/20176-5N/A-4N/A6/30/20174-5N/A-3N/A3/31/20173-5N/A-3N/A12/31/20162-4N/A-3N/A9/30/20161-3N/A-3N/A6/30/20161-4N/A-3N/A3/31/20161-4N/A-4N/A12/31/20151-4N/A-4N/A9/30/20150-4N/A-4N/A6/30/20150-4N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2INVの予測収益成長が 貯蓄率 ( 1.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2INVの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2INVの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2INVの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2INVの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2INVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/05 20:39終値2026/01/06 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋2invest AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Andrew Murray DarleyCavendishMark BrewerCavendishChristian OrqueraFirst Berlin Equity Research GmbH1 その他のアナリストを表示
お知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.
New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).
お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.
New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).
お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.
分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...
New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).
New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).
お知らせ • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022
Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
お知らせ • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.
お知らせ • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.
お知らせ • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.
Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.